PFE along with BioNTech SE BNTX announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of $93.00. The company’s shares closed last Friday ...

Fintel reports that on September 17, 2024, Jefferies upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS ...

With a volume of 492,652, the price of BNTX is up 6.46% at $111.78. RSI indicators hint that the underlying stock may be ...

BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...

BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.

UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...